Serum Interleukin‑6 and Interleukin‑8 are Sensitive Markers for Early Detection of Pyelonephritis and Its Prevention to Progression to Chronic Kidney Disease

Mojgan Mazaheri

Abstract


Background: Pyelonephritis is the most common bacterial infection in children that can cause renal failure if not diagnosed or treated early. We used serum biomarker interleukins (IL‑6 and IL‑8) and then confirmed the results by the findings dimercaptosuccinic acid (DMSA) scan to distinguish upper‑tract infection from lower‑tract infection.

Methods: Serum IL‑6 and IL‑8 were measured in 57 children with newly diagnosed untreated urinary tract infection (UTI) documented by a positive urine culture. All children had a DMSA to determine whether serum IL6, IL‑8 can be used as a marker to predict upper‑tract from lower‑tract infection. IL‑6 and IL8 were determined by the enzyme link immunosorbent assay (ELISA) technique.

Results: Of the 57 patients, 24 (42%) had renal parenchymal lesions on the DMSA scan. Patients with abnormal DMSA had significantly higher serum IL‑6 and IL‑8 compared with those with normal DMSA scan (187.1 ± 113.1 ng/mL vs. 396.1 ± 246.0 ng/mL, P = 0.005; and 165 ± 76.1 ng/mLvs. 190.8 ± 60.8 ng/mL, P = 0.026, respectively). Pyelonephritis was more frequent in children younger than 20 months old (n = 36, 63%, P < 0.005) and more prevalent in girls (n = 36, 63%, P = 0.005). Serum IL‑6 had a sensitivity of 67.3% and a specificity of 63.0% and serum IL8 had a sensitivity of 80.1% and a specificity of 73.5% in the differential diagnosis of pyelonephritis and cystitis (P = 0.03).

Conclusions: Serum levels of IL‑6 and IL‑8 are both sensitive biomarkers of UTI and can discriminate the upper from lower tract urinary infections. Determination of these biomarkers may help to identify patients with acute pyelonephritis and need for DMSA study


Keywords


Children; cystitis; dimercaptosuccinic acid scan; interleukin‑6; interleukin‑8; pyelonephritis

Full Text:

PDF

References


Foxman B, Brown P. Epidemiology of urinary tract infections:

Transmission and risk factors, incidence, and costs. Infect Dis

Clin North Am 2003;17:227‑41.

Paintsil E. Update on recent guidelines for the management of

urinary tract infections in children: The shifting paradigm. Curr

Opin Pediatr 2013;25:88‑94.

Dulczak S, Kirk J. overview of the evaluation, diagnosis, and

management of urinary tract infections in infants and children.

Urologist Nurs 2005;25:185‑91.

Balighian E, Burke M. Urinary btractrial infections in children.

Pediatr Rev 2018;39:3‑12.

Urinary tract infection. Clinical practice guidelines for the

diagnosis and management of the initial; UTI in febrile infants

and children 2 to 24 months. Pediatrics 2011;128:595-610. www.

pediatrics.org/chi/doi/10.1542/peds. 2011.1330.

Puseljic S, Arambasic J, Gardasnanic J, Milan V, Puseljic I,

Sipl M. The value of Tc99m‑DMSA renal scintigraphy in

evaluation of severity of parenchyma lesions in children with

acute urinary tract infection. Acta Med Croatica 2003;57:5‑10.

Garin EH, Olavarria F, Araya C, Broussain M, Barrera C,

Young L. Diagnostic significance of clinical and laboratory

findings to localize site of urinary infection. Pediatr Nephrol

;22:1002‑6.

Deo SS, Vaidya AK. Elevated levels of secretory

immunoglobulin A (sIgA) in urinary tract infections. Indian J

Pediatr 2004;71:37‑40.

Kjolvmark C, Pahlman L, Akesson P, Linder A. Heparin‑binding

protein: A diagnostic biomarker of urinary tract infection in

adults. Open Forum Infect Dis 2014;1:ofu004. doi: 10.1093/ofid/

ofu004.

Mantur M, Kemona H, Dabrowska M, Dabrowska J,

Sobolewdki S, Prokopowicz J. Alpha 1‑microglobin as a marker

of proximal tubular in urinary tract infection in children. Clin

Nephrol 2000;53;283‑87.

Vigano A, Assael BM, Dalla Villa A, Gagliardi L, Principi N,

Ghezzi P, et al. N‑acetyl‑beta‑D‑glucosaminidase (NAG)

isoenzyme in children with upper and Lower urinary tract

infections. Clin Chim Acta 1983;130:297‑304.

Kotoula A, Gardikis S, Tsalkidis A, Mantadakis S,

Zissimopoulos A Kambori K, et al. Procalcitonin for the early

prediction of renal parenchymal involment in children with UTI:

Preliminary results. Int Urol Nephrol 2009;41:393‑9.

Gurgoze MK, Akarsu S, Yilmaz E, Godekmerdan A, Akca Z,

Ciftci I, et al. Proinflammatory cytokines and procalcitonin in

children with acute pyelonephritis. Pediatr Nephrol 2005;20:1445‑8.

Nanda N, Juthani‑etha M, Novel biomarkers for the diagnosis

of urinary tract infection‑a systemic review. Biomark Insights

;4:111‑21.

Olszyna DP, Vermeulen H, Baan AH, Speelman P, van Deventer SJ,

Gouma DJ, et al. Urine interleukin‑8 is a marker for urinary tract

infection in postoperative patients. Infection 2001;29:274‑7.

Azab S, Zakaria M, Raafat M, Seief H. The combination of

urinary IL‑6 and renal biometry as useful diagnostic tools

to differentiate acute pyelonephritis from lower urinary tract

infection. Int Braz J Urol 2016;42:810‑6.

Sheu JN, Chen MC, Lue KH, Cheng SL, Lee IC, Chen SM,

et al. Serum and urine levels of interleukin‑6 and

interleukin‑8 in children with acute pyelonephritis. Cytokine

;36:276‑82.

Altman DG, Anderson PK. Calculating the number needed

to treat for trials where the outcome is time to event. BMJ

;319:1492‑5.

Otto G, Burdick M, Strieter R, Godaly G. Chemokine response

to febrile urinary tract infection. Kidney Int 2005;68:62‑70.